Description
Compound information
Retatrutide, also abbreviated RETA and identified by the development code LY3437943, is an investigational peptide studied for activity at the GIP, GLP-1 and glucagon receptors. These are three distinct receptor targets; “GLP-3”
Attached analytical report
- Testing provider: Janoshik.
- Report number: 204906.
- Sample label: Retatrutide 10MG.
- Batch: RT10-01.
- Analysis date: 20 July 2026.
- Reported content: 10.65 mg.
- Reported purity: 99.514%.
How to interpret these results
The figures above describe the sample identified in the attached report. Purity percentage and measured content are different measurements. A purity result does not establish sterility, clinical safety or regulatory approval.
Retatrutide product format
This listing supplies lyophilised research material in a glass vial. Lyophilised means freeze-dried; it is distinct from a liquid dropper formulation. Check the selected variant and the supplied label when identifying the material.
Related research compounds
For separate compounds with different receptor profiles, review our tirzepatide and semaglutide listings. These molecules are not interchangeable.
Does this report cover every variant?
The attached report identifies a specific 10 mg sample and batch RT10-01. For documentation relating to another size or lot, contact NuroLabs Research with the variant and batch number. Material is supplied for laboratory research only.


Reviews
There are no reviews yet.